Voices

Jennifer S Buell: The Extraordinary Science and Unwavering Commitment of MiNK Therapeutics

Jennifer S. Buell/LinkedIn

Aug 15, 2025, 12:10

Jennifer S Buell: The Extraordinary Science and Unwavering Commitment of MiNK Therapeutics

Jennifer S Buell, President and Chief Executive Officer at MiNK Therapeutics, shared a post by MiNK Therapeutics, on LinkedIn, adding:

“Thank you Dr. Gevorg Tamamyan, CancerWorld, and our brilliant team at MiNK Therapeutics! I’m deeply honored by this feature – but even more proud of what it represents: the extraordinary science and unwavering commitment of our team.

The real story is about our incredible scientists and their relentless drive to create better treatments and more options for patients – and about the patients themselves, who entrust us with their fight and inspire us to push the boundaries of what’s possible. Seeing patients with metastatic cancer return to life after years of treatment failures, when hope seemed gone — these are the moments that fuel our mission.

Every milestone is the result of a team effort – from our scientists and clinicians to our global collaborators and partners. Thank you for believing in the power of iNKT cell therapy to restore immunity and change outcomes.

Here’s to continuing the work – together.”

Quoting MiNK Therapeutics‘s post:

“MiNK Therapeutics is so proud to celebrate our President and CEO, Dr. Jennifer S. Buell, on her feature in CancerWorld magazine by Dr. Gevorg Tamamyan – highlighting her journey from patient to scientist to biotech leader, and MiNK Therapeutics groundbreaking work with iNKT cell therapy.

In the interview, Dr. Jennifer S Buell shares the science, the mission, and the human stories driving MiNK — including two recent cases published in Nature Portfolio Oncogene that demonstrate:

– 49-year-old patient with metastatic testicular cancer — treated with MiNK cells, achieved complete remission after 7 prior treatment failures, and is thriving two years later with no further treatment.
– Patient with refractory gastric cancer — achieved a durable, profound response when no options remained.

These results reflect what makes MiNK different:

·      Global access – Off-the-shelf, cryopreserved iNKT cells that can be shipped anywhere.
·      No toxic conditioning – Designed to be given like a standard infusion.
·      Restoring immunity – Giving patients a second chance to fight.

We’re proud of Dr. Buell’s leadership and vision — and grateful to our collaborators, partners, and the patients who make this work possible.

Read Dr. Buell’s full CancerWorld feature here.”

Jennifer S Buell